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Abstract Central neurocytoma is generally considered to be a
benign tumor and the literature suggests that a cure may be
attained by surgery ± adjuvant focal irradiation. However, there
is a need for change in the therapeutic strategy for the subgroup
of patients with aggressive central neurocytoma. An example
case is presented and the literature on central neurocytoma
cases with malignant features and dissemination via the cere-
brospinal fluid is reviewed and the radiotherapeutic strategies
available for central neurocytoma treatment is discussed.
Nineteen cases including the present report with a malignant
course and cerebrospinal fluid dissemination have been de-
scribed to date, most of them involving an elevated MIB-1
labeling index. Our case exhibited atypical central neurocytoma
with an initially elevatedMIB-1 labeling index (25–30 %). The
primary treatment included surgery and focal radiotherapy.
Three years later the disease had disseminated throughout the
craniospinal axis. A good tumor response and symptom relief
were achieved with repeated radiation and temozolomide che-
motherapy. Central neurocytoma with an initially high prolifer-
ation activity has a high tendency to spread via the cerebrospi-
nal fluid. The chemo- and radiosensitivity of the tumor suggest
a more aggressive adjuvant therapy approach. Cases with a
potential for malignant transformation should be identified
and treated appropriately, including irradiation of the entire
neuroaxis and adjuvant chemotherapy may be considered.
Keywords Central neurocytoma . Craniospinal
dissemination . Radiotherapy .MIB-1 labeling index
Introduction
Detection of the malignant transformation of central neuro-
cytoma (CN) at the time of the diagnosis is a rare feature of this
basically benign tumor, which is mainly associated with a favor-
able outcome. Before the entity of neurocytoma was described
by Hassoun et al. [1] in 1982 such tumors were referred to
intraventricular ependymomas or sometimes oligodendro-
gliomas. The latest WHO classification categorizes CN as a
grade II tumor [2–5]. Following the cellular origin, it has been
established that neurocytoma has the properties of bipotential
precursor cells, which can exhibit both glial and neuronal differ-
entiation [6]. Immunohistochemical studies have identified
markers of neuronal differentiation such as neuron-specific eno-
lase and synaptophysin [7, 8], this staining confirming the diag-
nosis of neurocytoma. This tumor entity, which accounts for only
0.1–0.5 % of all brain neoplasms [9–12], displays a slow and
benign clinical course with a low recurrence rate and a low
tendency to spread. Most neurocytomas arise from the septum
pellucidum, fornix or walls of the lateral ventricles, with relative-
ly frequent extension to the lateral and third ventricles, often
causing obstructive hydrocephalus in relation to the foramen of
Monro. The lesions are mainly located in the midline
supratentorially, and more commonly on the right side [13].
The occurrence of such tumors outside the cerebral ventricular
system is infrequent [14], reported first in 1989 [15], and these
lesions have been termed extraventricular neurocytomas. CN
develops mainly in young adults around the third decade of life
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[10, 12] (ranging from childhood to 70 years). It has been
detected with higher incidence in Asian populations, than among
Caucasians. The majority of the case reports and accounts of
small series originate from India [16–20], China [21–23], Japan
[7, 24–29], and Korea [11, 30–34]. Gross total resection (GTR)
ensures high progression-free and overall survival rates without
recurrence [5], but rare cases of more aggressive behavior with
dissemination in the craniospinal axis have been reported. On the
basis of the histological findings, such as nuclear atypia, anapla-
sia, vascular endothelial proliferation, focal necrosis, and/or an
increased mitotic index [2, 5, 35–37] a subgroup of this tumor
entity is defined as atypical neurocytoma. An MIB-1 labeling
index (MIB-1 LI) of ≥2 % or >3 % has been claimed to be
associated with a significantly poorer survival and to correlate
with a higher risk of relapse; moreover an MIB-1 LI of >4 %
correlates significantly with an unfavorable clinical course [38,
39]. Such a high proliferation index is quite uncommon and the
detection of malignant transformation at the time of the diagnosis
is extremely rare. Adjuvant radiotherapy (RT) has been stated to
be beneficial for patients with such atypical neurocytoma and
incomplete resection. In general, irradiation of the whole
craniospinal space is not recommended, but evidence has recent-
ly been accumulating of tumors that disseminate in the central
nervous system.
Presentation of Our Example Case
In February 2007, a 40-year-old man presented to our hospital
with a history of a few weeks of visual impairment, and
diplopia. MRI revealed a mass at the bottom and in the poste-
rior third of the third ventricle, which constricted the aqueduct
and caused an occlusive hydrocephalus. Via an endoscopic
ventriculostomy, aspiration biopsy was performed. The
cytopathological analysis demonstrated a cell-dense tissue,
with mild cellular atypia reminiscent of ependymal cells. A
focal rosette structure was observed, but there was no
glomeruloid vessel proliferation, necrosis, palisade necrosis or
mitosis. At that time a WHO grade II ependymoma was diag-
nosed. One week later, GTR of the tumor was carried out
through an occipital osteoplastic craniotomy. In the early post-
operative period the patient was somnolent and displayed slow-
ness of movements. Because of the abnormality of the CSF
circulation, a ventricular drain was inserted. Several febrile
episodes recurred and lumbar punctures demonstrated an ele-
vated leukocyte count in the CSF; parenteral antibiotic was
therefore administered, which resulted in an improvement of
the condition of the patient and the circulation of the CSF
normalized. The patient still presented diplopia, but no other
neurological symptoms.
Cytopathological analysis demonstrated a cell-dense, well-
vascularized tumor tissue. The nuclei were normal, and the
cytoplasm was moderately granulated. The cells were positive
for synaptophysin and negative for GFAP. The MIB-1 LI was
25–30 %. These findings corresponded to a diagnosis of
WHO grade II CN (Figs. 1, 2 and 3).
The patient was prepared for whole-neuraxis irradiation,
but the CSF was negative for tumor cells and there was no
suggestion in this respect in the literature overview, so he
finally participated in adjuvant, local RT by the 3D conformal
technique with a cummulative dose of 60 Gy in daily fractions
of 1.8 Gy to the primary tumor bed.
Until 2010 the patient was symptom-free, but in March of
that year there were signs of muscle weakness, an increase in
the deep tendon reflexes, moderate numbness in the left arm
and paresthesia in the lateral proximal region (headzone C 7–
8). A spinal MRI showed numerous small cervical, two
thoracal and several lumbar, mostly extramedullary manifes-
tations (Fig. 4.). Reoperation was performed and all tumor-
seeming tissue was removed from the thoracal IV-VI region
through hemilaminectomia and dura mater opening. The post-
operative period was uneventful. Cytopathological analysis
indicated a hypercellular, undifferentiated tumor tissue.
Moderate cell atypia and several mitoses were observed.
Immunohistological analysis demonstrated GFAP and CK-
KL1 negativity, synaptophysin positivity, a highly positive
MIB-1 LI of >40 %, NF: +/−, and CD99: +/−. This was
characteristic of malignantly transformed, disseminated CN of
WHO grade III. Postoperative, conformal irradiation of the
whole spinal cord was performed in a total dose of 36 Gy in
conventional fractionation, and a 10 Gy boost was delivered to
the tumor bed in the thoracal IV–VI region.
In November 2010, the patient presented with severe pain in
the shoulders, numbness in both arms and hands and moderate
muscle weakness in the right arm. CT showed moderate tumor
progression in the cervical spinal cord. At that time the patient
underwent simultaneous chemoradiotherapy with 200 mg/m2
Fig. 1 Microphotograph of a central neurocytoma (hematoxylin and
eosin stain, 40×). Well-vascularized tumor tissue and numerous round
nuclei with a moderately granulated cytoplasm
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temozolomide five times per week in 28-days cycles and
received an irradiation dose of 22.5 Gy in 1.5 Gy daily fractions
to the cervical spinal region. He was then placed on 200 mg/m2
temozolomide monotherapy. He remained stable and
symptom-free, and the repeated MRI examinations showed
mild tumor regression until November 2011, when the
follow-up MRI detected tumor recurrence in the left frontal
lobe, in the occipital lobes on both sides, and in the left
cerebellum (Figs. 5 and 6). Reirradiation was carried out to
the whole brain in a cumulative dose of 27 Gy in 1.8 Gy daily
fractions, with initial tumor bed avoidance, and an additional
boost dose of 8 Gy in 1 Gy daily fractions to the cerebral and
cerebellar manifestations. For a few months the good
condition of the patient persisted, but a slow deterioration of
his physical performance started in February 2012 and he
died in April 2012, 62 months after the initial diagnosis and
operation. Permission for autopsy was not granted by the
family.
Discussion
There has so far been no randomized clinical trial involving
CN because of the rarity of this tumor. Only case reports,
retrospective case studies and meta-analyses of small numbers
of patients are available with therapeutic recommendations.
Fig. 2 Microphotograph of a central neurocytoma (40×) displaying
strong synaptophysin positivity
Fig. 3 Microphotograph (40×) demonstrating the immunoreactivity of
Ki-67. The MIB-1 LI was reported to be 25–30 %
Fig. 4 Axial T2-weighted MRI showing hyperintense frontal metastasis
Fig. 5 Sagittal T1-weighted MRI showing hyperintense, contrast-en-
hancing metastases with perifocal edema in the left cerebellum and
occipital lobe
Clinical Course of Central Neurocytoma with Malignant Transformation 321
GTR provides the best local control and survival rates.
Postoperative irradiation is beneficial after STR and for atyp-
ical CN cases [2, 40]. Peak et al. [41] reported on 6 cases of
CN (no allusion to the typ of CN), who underwent postoper-
ative RT after GTR (3 cases) or STR (3 cases). The patients
were treated with Co-60 gamma-irradiation. The median total
dose to the primary tumor was 54 Gy. At the last follow-up,
the KPS scores had deteriorated, due to white-matter demye-
lination. This report demonstrates that RT can control residual
CN effectively and is beneficial, but more sophisticated irra-
diation techniques should be used to avoid serious late
sequelae.
There have been several reports on small numbers of CN
cases treated with conformal, adjuvant RT. Kim et al. [31]
concluded that better local control rates can be achieved with
RT. Schild et al. [42] and Rades et al. [43] retrospectively
analyzed the available CN small-series literature reports and
archives from their institution (32 and 85 cases, respectively).
Those authors concluded that postoperative RT should be
considered only in cases of STR and should involve only the
initial tumor bed, because CNs neither infiltrate the brain
parenchyma nor metastasize.
Rades et al. [44] reviewed and retrospectively analyzed 89
published incompletely resected cases of CN and recommended
a guideline for the local RT: the target volume should include the
preoperative tumor volume and 2 cm safety margin and should
be irradiated with a total dose of 54–62.2 Gy. Leenstra et al. [2]
likewise concluded that postoperative RTsignificantly improved
the local control rate. They confirmed a nonsignificant tendency
toward a better local control rate at 5 years when the MIB-1 LI
was ≤2 %. This demonstrated that the MIB-1 LI could be used
as a predictive marker of the clinical outcome. Several reports
have been published on the usage and effectiveness of the
gamma knife and stereotactic radiosurgery (SRS) for typical
CN [34, 45].
In opposite to the localised benign CN, 19 cases including
the present report have been described in the literature with
unfavorable clinical course and rapid progression: high rates
of local recurrence and craniospinal dissemination prior to the
diagnosis or following surgical resection (Table 1). 11 of the
13 patients for whom data were accessible had an initial MIB-
1 LI >2 %. The MIB-1 LI was not significantly higher among
the patients who died because of disease progression. For the
group of patients in whom the first tumor recurrence or
dissemination occurred within 12 months, a higher mean
MIB-1 LI was observed (mean 17.82 %, range 4.4–37.3 %).
There was a nonsignificant tendency toward an unfavorable
clinical course if the MIB-1 LI was initially elevated. The
same phenomenon was observed for the patients who devel-
oped spinal metastases, who exhibited an initial mean MIB-1
LI of 13.4 %.
There were no differences in age and gender distribution
and in localisation between the typical and atypical CN.
Malignant CN arises mainly from the septum pellucidum
(n =4), fornix or walls of the ventricles (lateral (n =8), third
and (n =1), fourth ventricles (n =1)) with relatively frequent
spreading to the surrounding structures: to the thalamus
(n =5), the frontal lobe (n =1) and the ventricles(n =4) and in
one case the tumor was alreadymultifocally spread. Due to the
diffuse growth toward the adjacent structures GTR could be
carried out in only 3/18 cases, 13 patients underwent STR, and
2 biopsy only. Reoperation was carried out in 4 cases.
16/18 patients received adjuvant treatment, i.e. RT ± che-
motherapy. A huge variety of RT techniques (SRS=3, confor-
mal RT=12), doses (25–66 Gy) and cytotoxic agents and
combination were used (etoposide, carboplatin, cyclophos-
phamide, cisplatin, vincristine, cytarabine, ifosfamide, imatin-
ib, temozolomide, toptecan, thioTEPA, and nimustine). Four
patients received only chemotherapy and two patients did not
get any postoperative treatment. The whole craniospinal axis
was treated only in the cases with proven manifestation in the
spinal cord (n =2). In case 8 [51], 39.6 Gywas administered to
the entire neuraxis and an additional 14.4 Gy to the thoracal
spine, sequential to cyclophosphamide, etoposide, and cisplat-
in. In case 17 [58], the craniospinal axis was treated with
36 Gy, and a 20 Gy boost was given to the tumor bed and to
the upper cervical spine. Reirradiation was carried out in 3
cases, and diverse chemotherapeutic regimes were performed
for the treatment of recurrences. In our patient temozolomide
resulted in good response lasting for 12 months.
The clinical outcome was available for all cases. 7 patients
died because of tumor dissemination and disease progression.
Fig. 6 Transversal T1-weighted MRI showing hyperintense, contrast-
enhancing, intradural metastases in the thoracal spinal canal
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The estimated mean survival was 27.9 months (range 5–
46). 7 patients were in a stable condition at the time of
their last follow-up examination. The mean follow-up peri-
od was 32.4 month (range 7–72). 2 patients were in disease
progression at their last follow-up 15 and 7 months after
the first operation. 2 patients were disease-free 9 and
132 months after the first tumor removal. The estimated mean
progression-free survival was 15.3 months, ranging from 2 to
36 months.
One patient had multifocal disseminated disease at the
time of the diagnosis. In the other cases, recurrence was
always observed. CSF spreading was detected in 16/18 cases
(ventricular n =5 on average 11 months after the first opera-
tion and spinal metastases n =11 an average of 21.1 months
(range 5–36)). One patient exhibited peritoneal dissemination
through the ventriculo-peritoneal shunt 43 months after the
diagnosis.
In our case, we planned irradiation of the entire
neuraxis as initial therapy, but the literature review at that
time led us to change our treatment strategy to focal
irradiation only. Irradiation of the recurrencies resulted
in a good tumor response lasting from some months to
years. The clinical course of the disease proved the
inappropriateness of our decision on the postoperative
treatment (local irradiation only), because this review of
the separately reported malignant CN cases shows high
probability of spread via the CSF (89 %) and the tumor
exhibits good radiosensitivity.
Table 1 A summary of all the reported cases of central neurocytomas with a malignant course
A/S Localisation MIB-1
LI(%)
Chronologyof dissemination Treatment Progr. Follow-up
af D
Ref.
3,M 3rdv, l th – STR,24 mo LC, STR2, 19 mo rapid
LC & PD
ETO,CPT, DOXO, CTX 24 mo E43 mo [46]
3,M WholeCSA 6,7 Diffuse,multifocal with leptomeningeal dis VCR,CPT – SD18 mo [47]
5,M Rlat. v, r front 37,3;23,8 GTR,12 mo later R in frontal lobe/GTR,
5 mo later CSF spreading into frontal
horn of l lat v, 9 mo later R in 4th v,
2 mo later L3–L4 drop metastasis,
10 mo later multiple metastases
VCR,CDDP, CTX/R2 INN, locRT:
50 Gy + TMZ, TMZ/R3 ITAra-C +
SRS:16 Gy/R4 Ara-C, TOPO, CPT,
IFO, thioTEP, + ASCT, RT: 36 Gy +
6 Gy to L3-L4/R5 RT, ETO
12 mo SD46 mo [48]
19,F Lth, lat vs 4,6 STR,2 mo later LR in l th l temp.,
2nd STR
RT 2 mo E5 mo [49]
21,F Latvs – Biopsyand RT, 15 mo later dis RT50 Gy 15 mo Dis15 mo [16]
22,F SP,3rd, lat. vs 3,3 GTR,36 mo later R in 3rd, 4th and
lat vs, Th8
ETO,CDDP, CTX – SD36 mo [50]
22,F Rlat and 3rd v 1,8;4,1 STR,20 mo later R in lat v, 2nd STR,
14 mo later dis to lat vs and spinal
leptomeninges
ETO,CDDP, CTX 20 mo SD34 mo [50]
22,F SP,3rd, lat vs – GTR,36 mo LC, dis walls of the
vs & at Th8
AfterP CTX, ETO, CDDP, RT: 39,
6 Gy CSA + 14,4 Gy to Th8
36 mo SD72 mo [51]
31,F Rlat v, r th 15 STR,24 mo later LC, multiple dis
in CSA
IFO,CDDP, ETO, RT: 50 Gy 24 mo E37 mo [52]
31,F SP,lat vs mult 7–8 STR – – SD7 mo [53]
34,M Corp.callos 25 STR,12 mo later LC and spinal dis SRS:25 Gy, after R RT: 60 Gy,
CDDP, ETO
12 mo E23 mo [54]
71,F Corp.callos 14,4 STR RT:60 Gy, ACNU 22 mo E46 mo [54]
35,F Llat v 4,6 Biops,11 mo P, spinal dis at Th4
level, STR
RT:brain 66 Gy, spinal cord
Th2–Th5 46 Gy
11 mo SD14 mo [55]
42,M Latvs high STR,24 mo later meningeal dis 24 mo E24 mo [56]
43,M SP – STR,2 mo later dis to v’s walls RT:60,6 Gy 2 mo E17 mo [57]
46,M Llat v, th – STR,5 mo later P in 3rd v, 2 mo
later dis
RT:60 Gy, after R RT: 56 Gy 5 mo InP 7 mo [57]
59,F 4thv <1 D,7 mo STR, dis in v, cerebell & C
spinal cord
RT:36 Gy CSA + 20 Gy to
tumor beds
5 mo DSF9 mo [58]
7,8 STR,R, dis into 4th v RT,ChT DSF132 [59]
ACNU nimustine, Ara-C cytarabine, ASCT autologous stem cell transplantation, CDDP cisplatin, ChT chemotherapy, CPT carboplatin, CSA
cerebrospinal axis, CTX cyclophosphamide,D diagnosis, dis dissemination,DOXO doxorubicin, ETO etoposide, E exitus,GFAP glial fibrillary acidic
protein, IFO ifosfamide, IHC immunohistochemistry, INN imatinib, IT intrathecal, l left, LC local recurrence, mo months, Neu-N neuron-specific
nuclear protein, NF neurofilament, NSE neuron-specific enolase, P progression, PD peritoneal dissemination, R recurrence, r right, SD standard
disease, SP Septum pellucidum, SRS stereotactic radiosurgery, Syn synaptophysin, th thamus, TOPO topotecan, TMZ temozolomide, v vtricle, VCR
vincristine
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Conclusions
There is currently no standard accepted therapeutic option for
atypical CN; a rare central nervous system malignancy. The
patients are treated with a large variety of different ap-
proaches. The conclusions drawn from meta-analyses of re-
ports on benign CN can not be applied in cases with aggres-
sive behavior. Our systematic evaluation of the available
sporadic case reports has demonstrated that the cases with
potential malignant transformation should be differentiated,
and treated accordingly. Apart from the nuclear atypia, ana-
plasia, vascular endothelial proliferation, focal necrosis, and/
or an increased mitotic index, correct evaluation of the MIB-1
LI can help in the identification of these patients. In that cases
after the largest possible surgical removal, adjuvant neuroaxis
irradiation should be considered.
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